Who are "Conventional" regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Wellbutrin, MAR, NB, bupropion immediate release (IR), Habitual medication, Welbutrin XL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

"Conventional" regimen — Competitive Intelligence Brief

"Conventional" regimen ("Conventional" regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor. Area: Psychiatry.

marketed Norepinephrine-dopamine reuptake inhibitor Psychiatry Biologic Live · refreshed every 30 min

Target snapshot

"Conventional" regimen ("Conventional" regimen) — Pablo Rodríguez del Rio. This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
"Conventional" regimen TARGET	"Conventional" regimen	Pablo Rodríguez del Rio	marketed	Norepinephrine-dopamine reuptake inhibitor
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	marketed	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
MAR	MAR	Noah Pharmaceuticals, Inc.	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRIs)
NB	NB	Orexigen Therapeutics, Inc	marketed	Combination antiobesity agent (opioid antagonist + norepinephrine-dopamine reuptake inhibitor)	Opioid receptors (naltrexone); norepinephrine and dopamine transporters (bupropion)
bupropion immediate release (IR)	bupropion-immediate-release-ir	Pfizer	marketed	Norepinephrine-dopamine reuptake inhibitor	Dopamine transporter, Norepinephrine transporter
Habitual medication	Habitual medication	Hospital Universitario de Canarias	marketed	Norepinephrine-dopamine reuptake inhibitor
Welbutrin XL	Welbutrin XL	Massachusetts General Hospital	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor class)

Breath of Life International Pharma Ltd · 1 drug in this class
Hospital Universitario de Canarias · 1 drug in this class
Iowa City Veterans Affairs Medical Center · 1 drug in this class
Pablo Rodríguez del Rio · 1 drug in this class
Pfizer · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). "Conventional" regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab